NFE2L2 and neoplasm: The proposed clinical use of specific types of selenium is not as a cytotoxic drug but rather as a selective modulator of the therapeutic efficacy and toxicity of anticancer therapeutics through targeting HIFS, miRs, and Nrf2, that regulate targets implicated in ‘drug’ resistance and increased tumor angiogenesis.